Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor

PAMSARC is a non-commercial interventional Phase 2 clinical trial of academic research institutions, with its primary goal being to improve medical treatment of fusion driven Desmoplastic small round cell tumor (DSRCT) and Synovial sarcoma (SySa) in young adults and adolsecents with male predominance. Current management of DSRCT and SySa includes chemotherapy, radiation and aggressive cytoreductive surgery. Despite advances in multimodal therapy, outcomes remain poor with frequent disease recurrence and very limited options for patients with advanced disease. Selected somatostatin receptor (

Trial Details

NCT ID
NCT06456359
Phase
PHASE2
Sponsor
University Hospital Heidelberg
Status
RECRUITING
Cancer Type
Sarcoma
Interventions
  • Signifor
Locations (sample)
  • Heidelberg, Baden-Wurttemberg, Germany|49.40768,8.69079
  • Stuttgart, Baden-Wurttemberg, Germany|48.78232,9.17702
  • Stuttgart, Baden-Wurttemberg, Germany|48.78232,9.17702
  • Essen, North Rhine-Westphalia, Germany|51.45657,7.01228

Key Eligibility Criteria

  • Patients meeting all of the following criteria are considered for enrolment into the trial:
  • Reference pathological proven diagnosis of DSRCT in any stage; or Reference pathological proven diagnosis of SySa, IRS III, metastatic or relapsed …
  • High SSTR2/3/5 mRNA expression, as determined by RNA sequencing in the DKFZ/NCT/DKTK MASTER (ClinicalTrials.gov ID: NCT05852522) or INFORM programs.
  • Stable disease, partial or complete response after completion of standard treatment

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Sarcoma Trials on Trialify →